This is a working overview of Research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-16. Anything still debated is marked as such rather than presented as settled.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
=== Origins and distribution === Originating in North America, the Jerusalem artichoke can now be found in several countries in North and South America, Europe, Asia, and Australia. In Central Europe it is one of the most expanding invasive plant species. It can grow in many geo-climatic regions and different types of soils. However, Jerusalem artichoke prefers moist habitats and seems to be less tolerant of dry conditions.
==== Africa ==== In May 2010, Southern Sun Hotels South Africa signed an agreement with Starbucks to brew Starbucks coffees in select Southern Sun and Tsonga Sun hotels in South Africa. The agreement was partially reached so Starbucks coffees could be served in the country in time for the 2010 FIFA World Cup hosted by South Africa.
=== Awards and honours === Winner of the CA/Zurich Business Leader Award in 2002 Winner of the inaugural Trans-Tasman Business Leader Award in 2005 Awarded a Doctor of Business honoris causa by RMIT University in 2008 Appointed Officer of the Order of Australia (AO) in 2010 for service to the development of the transport and logistics industries through strategic leadership and promotion of corporate social and environmental responsibility, and to the community through philanthropic support of sporting and medical research organisations. Little is also a Fellow of the Australian Institute of Company Directors and a Fellow of the Chartered Institute of Logistics and Transport (FCILT).
Sources: en.wikipedia.org
=== Guest appearances === Snobs (13 January 2000) – 1 episode Loose Women (16 September 2011, 1 March 2012, 26 April 2013, 3 October 2013, 24 February 2014, 4 February 2016, 4 March 2016, 3 March 2017, 6 April 2017, 7 September 2017, 2 March 2018, 27 June 2018, 11 February 2019, 20 February 2019, 19 March 2019, 6 August 2020) – 16 episodes I'm a Celebrity...Get Me Out of Here! NOW! (23–25 November 2011, 16 November 2015) – 4 episodes Peter Andre: My Life (14 December 2011) – 1 episode That Sunday Night Show (8 January 2012) – 1 episode Celebrity Juice (15 March 2012, 9 May 2013, 11 April 2019, 24 October 2019, 12 November 2020) – 5 episodes This Morning (30 March 2012, 2 April 2012, 4 April 2012, 31 August 2012, 19 September 2012, 18 January 2013, 5 April 2013, 19 April 2013, 24 April 2013, 28 November 2014, 3 December 2014, 4 December 2014, 13 May 2015, 5 February 2016, 4 July 2016, 2 August 2016, 30 April 2018, 1 October 2018, 7 January 2019, 23 January 2019, 4 February 2019, 11 February 2019, 14 August 2019, 18 December 2019, 28 June 2024) – 25 episodes The Big Quiz (15 April 2012) – 1 episode 8 Out of 10 Cats (15 June 2012, 25 January 2013, 28 January 2020) – 3 episodes Big Brother's Bit on the Side (4 July 2012, 28 July 2013, 13 May 2015, 16 June 2017) – 4 episodes Let's Do Lunch with Gino & Mel (29 August 2012) – 1 episode Celebrity Big Brother's Bit on the Side (6 September 2012, 9 January 2013, 1 September 2013, 19 August 2014, 29 January 2015, 2 February 2016, 4–5 February 2016, 1 August 2017) – 9 episodes Fake Reaction (3 January 2013) – 1 episode 8 Out of 10 Cats Does Deal or No Deal (4 January 2013) – 1 episode Food Glorious Food (24 April 2013) – 1 episode Sunday Side Up (29 December 2013) – 1 episode Who's Doing the Dishes? (3 October 2014) – 1 episode Phillip's Live 24-Hour TV Marathon (1 December 2014) – 1 episode Mel & Sue (14 January 2015) – 1 episode If Katie Hopkins Ruled the World (6 August 2015) – 1 episode Kendra on Top (21 August 2015) – 1 episode Keep It in the Family (22 August 2015) – 1 episode Safeword (27 August 2015) – 1 episode Tina Malone: My New Body (1 October 2015) – 1 episode Tricked (27 October 2015) – 1 episode The Wright Stuff (4 February 2016) – 1 episode Virtually Famous (8 March 2016) – 1 episode In Therapy (5 July 2016) – 1 episode It's Not Me, It's You (29 July 2016) – 1 episode Sky News (25 October 2016, 6 September 2024) – 2 episodes Alan Carr's Specstacular (31 December 2016) – 1 episode Through the Keyhole (4 February 2017) – 1 episode BBC Radio 1 Teen Awards (22 October 2017, 21 October 2018) Celebrity 100% Hotter (25 January 2018) – 1 episode The Generation Game (1 April 2018) – 1 episode Livin' with Lucy (10 September 2018) – 1 episode ReFreshers Week Presented By Strongbow (1 October 2018) – 1 episode Your Face or Mine? (3 October 2018) – 1 episode Good Morning Britain (30 October 2018, 19 December 2018, 4 February 2019, 1 April 2019, 24 June 2019, 7 August 2019, 13 November 2019, 25 November 2019, 8 December 2020) – 9 episodes I'll Get This (4 December 2018) – 1 episode Lorraine (4 January 2019, 18 January 2019, 23 January 2019, 8 March 2019, 9 September 2019, 30 September 2019, 15 November 2019, 11 December 2023) – 8 episodes The Jonathan Ross Show (9 March 2019) – 1 episode The Real Housewives of Cheshire (22 April 2019, 11 November 2019) – 2 episodes The Crystal Maze (21 June 2019) – 1 episode Celebrity Catchphrase (31 August 2019) – 1 episode MTV Cribs UK (16 September 2019, 7 December 2020) – 2 episodes Dancing on Ice at Christmas (22 December 2019) – 1 episode The Big Narstie Show (7 February 2020) – 1 episode Inside Missguided: Made in Manchester (12 August 2020) – 1 episode Rolling In It (15 August 2020) – 1 episode Shopping with Keith Lemon (25 October 2020) – 1 episode Celebrity Supply Teacher (17 November 2020) – 1 episode The Wheel (19 December 2020, 18 December 2021) – 2 episodes Dancing on Ice (24 January 2021) – 1 episode Piers Morgan's Life Stories (11 February 2021) – 1 episode RuPaul's Drag Race UK (18 February 2021) – 1 episode Mel Giedroyc: Unforgivable (23 February 2021) – 1 episode Sophie Ellis-Bextor's Kitchen Disco Danceathon (16 November 2021) – 1 episode Angela Scanlon's Ask Me Anything (27 November 2021) – 1 episode The Weakest Link (23 December 2021) – 1 episode Celebrity MasterChef: Christmas Cook-Off (23 December 2021) – 1 episode The Travel Show (4 February 2022) – 1 episode Springwatch (8 June 2022) – 1 episode The Big Breakfast (20 August 2022, 27 August 2022, 3 September 2022) – 3 episodes The Great Scott TreadMills Challenge (16 November 2022) – 1 episode The Greatest Snowman (26 December 2022) – 1 episode Mwy Na Daffs a Taffs (2 March 2023) – 1 episode Would I Lie to You? (24 March 2023) – 1 episode The Great Stand Up to Cancer Bake Off (26 March 2023) – 1 episode Late Night Lycett (14 April 2023) – 1 episode Steph's Packed Lunch (16 May 2023) – 1 episode The Comedy Roast for SU2C (3 November 2023) – 1 episode Celebrity Antiques Road Trip (28 November 2023) – 1 episode Blankety Blank (23 December 2023) – 1 episode The Underdog: Josh Must Win (3 April 2024) – 1 episode Drama Queens (1 May 2024) – 1 episode Who Do You Think You Are? (26 September 2024) – 1 episode Katy Perry: Night of a Lifetime (21 December 2024) – 1 episode Pointless Celebrities (25 January 2025) – 1 episode ITV Racing: Cheltenham Festival Live (13 March 2025, 12 March 2026) – 2 episodes I'm a Celebrity: Unpacked (17 April 2026, 20 April 2026) – 2 episodes
=== Mechanism of mineralization === Mineralization occurs in two phases: the vesicular phase and the fibrillar phase. Vesicular phase: Matrix vesicles, measuring 30-200 nm in diameter, are released from the apical membrane of osteoblasts into the newly formed bone matrix. These vesicles contain alkaline phosphatase, adenosine triphosphatase (ATPase), and inorganic pyrophosphatase, and act as seeding sites for hydroxyapatite crystal formation through localized enzymatic accumulation of calcium and phosphate. Role of alkaline phosphatase: Osteoblasts secrete alkaline phosphatase, which participates in bone mineralization by hydrolyzing pyrophosphate, an inhibitor of mineralization, thereby increasing local inorganic phosphate availability for hydroxyapatite formation. Crystal propagation: Crystal growth proceeds from initial foci in matrix vesicles to form spheroids, which gradually coalesce to form a network of apatite crystals. As the matrix matures, hydroxyapatite microcrystals are organized into a sophisticated composite within the collagen layer by nucleation in the protein lattice.
TIM is the protein transport machinery of the mitochondrial inner membrane that contains three essential TIM proteins: Tim17 and Tim23 are thought to build a preprotein translocation channel while Tim44 interacts transiently with the matrix heat-shock protein Hsp70 to form an ATP-driven import motor. ATP + H2O + mitochondrial protein [side 1] = ADP + phosphate + mitochondrial protein [side 2] 7.4.2.4 ABC-type chloroplast protein-transporting ATPase The enzyme appears in viruses and cellular organisms. Involved in the transport of proteins or preproteins into chloroplast stroma (several ATPases may participate in this process). ATP + H2O + chloroplast protein [side 1] = ADP + phosphate + chloroplast protein [side 2] 7.4.2.5 ABC-type protein transporter The expected taxonomic range for this enzyme is: Eukaryota, Bacteria. This entry stands for a family of bacterial enzymes that are dedicated to the secretion of one or several closely related proteins belonging to the toxin, protease and lipase families. Examples from Gram-negative bacteria include α-hemolysin, cyclolysin, colicin V and siderophores, while examples from Gram-positive bacteria include bacteriocin, subtilin, competence factor and pediocin. ATP + H2O + protein [side 1] = ADP + phosphate + protein [side 2] 7.4.2.6 ABC-type oligopeptide transporter A bacterial enzyme that interacts with an extracytoplasmic substrate binding protein and mediates the import of oligopeptides of varying nature. The binding protein determines the specificity of the system. Does not undergo phosphorylation during the transport process.
De Lima presented as witness an alleged member of Davao City-based vigilante group Davao Death Squad, Edgar Matobato, who testified that Duterte was involved in extrajudicial killings in the city. Duterte dismissed the allegations as fabricated, and the Senate committee formally terminated the inquiry on October 13, 2016, citing a lack of corroborating evidence. Shortly after, Duterte implicated De Lima in the illegal drug trade during her tenure as Justice Secretary under the Aquino III administration. Though De Lima denied the claims, she was later imprisoned in February 2017 due to the drug charges. Two months later, Matobato's lawyer, Jude Josue Sabio, filed charges for crimes against humanity with the International Criminal Court against Duterte and 11 other officials. Responding to public clamor, in October 2017, Duterte designated the Philippine Drug Enforcement Agency to lead anti-drug operations and temporarily barred the police from joining the raids. Through an executive order he issued in October 2018, Duterte instituted a more balanced approach to the drug problem by establishing the Philippine Anti-Illegal Drugs Strategy, which ordered all government departments and state universities and colleges to implement their own strategies in tackling the country's illegal drug trade; the order also urged local government units, non-government organizations, and private institutions to support and implement the Strategy.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.